Amgen Presents Positive Result For Phase-III Denosumab Trial
Study demonstrated superior efficacy as compared to Zometa
Amgen' phase-III trial evaluating denosumab versus Zometa (zoledronic acid) for bone metastases in 2,049 patients with advanced breast cancer, has met its primary and secondary endpoints. The trial also demonstrated superior efficacy compared to Zometa for denosumab.
Roger Perlmutter, Executive Vice President of R&D at Amgen, said: We are extremely pleased with the outcome of this important study, which shows that denosumab can reduce or delay the serious complications of bone metastases in breast cancer patients better than the current standard of care, and with a favorable benefit/risk profile.
These results underscore the importance of the RANK Ligand pathway in bone disease, and offer the promise of improved care for patients with advanced breast cancer. We look forward to reviewing the results from a second Phase 3 study of denosumab effects in advanced cancer patients later this year, he added.
Full efficacy and safety data will be submitted for presentation at an upcoming medical meeting in the second half of this year, said the company.
Related Insight
Suppliers Directory
Eka - Spherical Silica Packing Material for APIs
Kromasil is a high performance spherical silica packing material for analytical to industrial scale HPLC, and is available as bulk as well as in slurry-packed columns, from 2.1 mm up to 50 mm ID.
Suppliers
Aveflor - Production of Medical Devices and Drugs in Aerosol, Gel, or Powder
The Czech company AVEFLOR Corp. was founded in 1995. It has been producing liquid and powder aerosols since its foundation. In 2007, the company extended its range of technologies by including the production of emulsions and gels in plastic containers and in BOV aerosols.
Suppliers
Phage Consultants - Contamination Prevention Services
Contaminations are one of major threats in bioprocesses. If contamination occurs, it may result in complete paralysis of facility productivity. Although even the best protection do not guarantee they never occur, better prepared facility will recover faster, and the contamination will not turn into outbreak. The company Phage Consultants was created to help companies which production is based on microbial activities, to fight with and prevent from bacteriophages and other contaminants. Based on our research and experience we propose different ways of assistance: from personnel training, through consulting and process optimization, to help in development of new facilities. Phage Consultants can help you in avoiding contaminations and in recovery from contaminations, which already occurred.
Suppliers
Nycomed - Contract Services
Nycomed is a privately owned global mid-sized pharmaceutical company with a differentiated portfolio focused on branded medicines in the areas of gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
An Interview with Paul Gerteis
Published by Gerteis
White Papers
Life Sciences Product List 2012
Published by Randox
White Papers
Streamlining and Accelerating Change Control
Published by QUMAS
White Papers
How to Design a Clinical Data Warehouse
Published by NNIT
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.